Novel CDK2 Inhibitor INCB123667 Shows Promise in Ovarian Cancer
The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.
Related Articles
How can we treat patients with NSCLC who progress on EGFR TKIs?
Tony Mok, MD, Chinese University of Hong Kong, Hong Kong, China, comments on the challenges faced by patients with non-small cell lung cancer (NSCLC) who…
T-DXd Breakthrough Designation Signals New Era for HER2-Positive Metastatic Breast Cancer
FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved survival rates for patients.
OncLive – Clinical Oncology News, Cancer Expert Insights
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
AI and Innovation in Oncology
Arturo Loaiza-Bonilla, MD, MSEd, discusses the significant advancements and ongoing efforts in integrating artificial intelligence into oncology.
Tanning
Tanning outside or indoors can have dangerous consequences. Tanning damages your skin cells, speeds up skin aging and can lead to skin cancer. Learn more.
Luspatercept Misses Primary End Point, Shows Clinically Meaningful Secondary Benefits
Luspatercept shows promise in improving anemia in myelofibrosis patients, despite not meeting primary trial endpoints, highlighting ongoing treatment challenges.
Carboplatin/Paclitaxel to Immunotherapy Combinations: Evolving First-Line Options in Advanced SCAC
Panelists discuss how current NCCN guidelines for metastatic anal cancer recommend carboplatin-paclitaxel as preferred first-line therapy, with the recent addition of carboplatin-paclitaxel plus retifanlimab as…
FDA Issues CRL for RP1 in Advanced Melanoma
Replimune faces FDA hurdles for RP1, an innovative melanoma treatment, as it seeks a path forward after receiving a complete response letter.
Staged I-125 Eye Plaque Brachytherapy for the Treatment of Large Uveal Melanoma: A Single Institution Experience
Eye plaque brachytherapy (EPBT) is not routinely performed on large uveal melanomas (UM) as commercially available plaques often cannot ensure adequate coverage of the tumor…
Linvoseltamab Plus Carfilzomib Shows Manageable Safety in RRMM
Rajshekhar Chakraborty, MD, discusses the safety and tolerability of linvoseltamab with carfilzomib when used for the treatment of patients with relapsed/refractory multiple myeloma.